Olamufloxacin. Hokuriku Seiyaku.
Hokuriku is developing olamufloxacin, a quinolone antibiotic that inhibits DNA gyrase, for the potential treatment of various types of bacterial infection. It has reached late phase II clinical trials. An intravenous formulation is also under investigation [277817].